Takeda’s 1st Cell Therapy Up for PAFSC Review on Sept. 6

August 24, 2021
Takeda Pharmaceutical’s darvadstrocel will come up for review by a key health ministry panel on September 6 for the treatment of complex perianal fistulas associated with Crohn’s disease. If approved, it will be the company’s first allogeneic stem cell therapy...read more